Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $20
AbCellera Biologics Inc. 2026 Q3 - Results - Earnings Call Presentation
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15
AbCellera Biologics Inc (ABCL) (Q3 2026) Earnings Call Highlights: Breakthrough Hot Flash Data ...
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14
AbCellera (ABCL) Q3 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
AbCellera Reports Q3 2026 Business Results
AbCellera Biologics Q3 2026 Earnings Call Transcript
AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate
AbCellera (ABCL) Stock May Look Fully Priced On Book Value
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
AbCellera to Present at Upcoming Investor Conferences in November 2026
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.